[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-334594-105":59,"doc-detail-334594-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","inx-315-a-selective-cdk2-inhibitor-induces-cell-cycle-arrest-and-senescence-in-solid-tumors","INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors","","Cyclin-dependent kinase 2 (CDK2) is implicated in driving proliferation in cancers including those with CCNE1 amplification and in breast cancers that have developed resistance to CDK4/6 inhibitors. INX-315 is presented as a novel, potent, highly selective CDK2 inhibitor. Using cell-based assays, patient-derived xenografts, and transgenic mouse models, INX-315 promotes retinoblastoma protein hypophosphorylation and therapy-induced senescence in CCNE1-amplified tumors, reverses CDK4/6i resistance in breast cancer, and deepens suppression of E2F targets to delay resistance onset.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/inx-315-a-selective-cdk2-inhibitor-induces-cell-cycle-arrest-and-senescence-in-solid-tumors/334594/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/inx-315-a-selective-cdk2-inhibitor-induces-cell-cycle-arrest-and-senescence-in-solid-tumors/334594.png","ImageObject",300,407,{"name":92,"@type":93},"Anda","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What problem does the study address regarding CDK2 inhibition?","Question",{"text":112,"@type":113},"The precise effects of pharmacologic CDK2 inhibition are unclear because selective CDK2 inhibitors were lacking. The work introduces INX-315 to fill this gap and evaluate its impact on tumor cell behavior.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does INX-315 affect CCNE1-amplified tumors?",{"text":117,"@type":113},"INX-315 promotes retinoblastoma protein hypophosphorylation and therapy-induced senescence, leading to durable control of tumor growth in CCNE1-amplified contexts.",{"name":119,"@type":110,"acceptedAnswer":120},"How does INX-315 relate to resistance to CDK4/6 inhibitors in breast cancer?",{"text":121,"@type":113},"INX-315 overcomes breast cancer resistance to CDK4/6 inhibitors by restoring cell cycle control and re-establishing the chromatin architecture associated with CDK4/6i-induced therapy-induced senescence.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},334594,1790634693,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},962075006959,"https://ap-avatar.wpscdn.com/avatar/e0002397efbe92a78e?_k=1776741047341049297","RESEARCH ARTICLE  \nINX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence  \nin Solid Tumors   \nCatherine Dietrich1,2, Alec Trub3, Antonio Ahn1,2, Michael Taylor1,2, Krutika Ambani1,2, Keefe T. Chan1,2, Kun-Hui Lu1,2, Christabella A. Mahendra1,2, Catherine Blyth1,2, Rhiannon Coulson1,2, Susanne Ramm1,2, April C. Watt1,2, Sunil Kumar Matsa4, John Bisi3, Jay Strum3, Patrick Roberts3, and Shom Goel1,2  \nABSTRACT  Cyclin-dependent kinase 2 (CDK2) is thought to play an important role in driving proliferation of certain cancers, including those harboring CCNE1 amplification  \nand breast cancers that have acquired resistance to CDK4/6 inhibitors (CDK4/6i). The precise impact of pharmacologic inhibition of CDK2 is not known due to the lack of selective CDK2 inhibitors. Here we describe INX-315, a novel and potent CDK2 inhibitor with high selectivity over other CDK family members. Using cell-based assays, patient-derived xenografts (PDX), and transgenic mouse models, we show that INX-315 (i) promotes retinoblastoma protein hypophosphorylation and therapy-induced senescence (TIS) in CCNE1-amplified tumors, leading to durable control of tumor growth; (ii) overcomes breast cancer resistance to CDK4/6i, restoring cell cycle control while reinstating the chromatin architecture of CDK4/6i-induced TIS; and (iii) delays the onset of CDK4/6i resistance in breast cancer by driving deeper suppression of E2F targets. Our results support the clinical development of selective CDK2 inhibitors.  \nSIGNIFICANCE: INX-315 is a novel, selective inhibitor of CDK2 . Our preclinical studies demonstrate activity for INX-315 in both CCNE1-amplified cancers and CDK4/6i–resistant breast cancer. In each case, CDK2 inhibition induces cell cycle arrest and a phenotype resembling cellular senescence. Our data support the development of selective CDK2 inhibitors in clinical trials.  \nSee related commentary by Watts and Spencer, p. 386.  \nINTRODUCTION  \nGiven that cancer is fundamentally a disease of uncontrolled cellular proliferation, the development of therapies that specifically target cell cycle progression has been a long sought-after goal for the cancer drug development community (1) . However, many early attempts to develop inhibitors ofCDK were unsuccessful due to poor compound selectivity resulting in unfavorable toxicity profiles (2) . Indeed, the first FDA approval for a CDK inhibitor was not until 2015, when the selective CDK4/6i palbociclib entered clinical practice as treatment for hormone receptor (HR)-positive breast cancer (3) . As a class, the approved CDK4/6i have subsequently provided proof of principle that the selective targeting of CDKs not only reduces drug toxicity but can also significantly improve survival outcomes (1) .  \nCDKs 4 and 6 regulate a cell’s passage from the G1 to the S-phase of the cell cycle by phosphorylating and hence inactivating the retinoblastoma (Rb) tumor suppressor protein, which in turn derepresses E2F-mediated transcription. By blocking Rb phosphorylation, CDK4/6i induce G1 arrest and  \n1Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia. 2Peter MacCallum Cancer Centre, Melbourne, Australia. 3Incyclix Bio, Durham, North Carolina. 4Ayurveda Molecular Modeling, Telangana, Hyderabad, India.  \nC. Dietrich and A. Trub contributed equally to this article.  \nCorresponding Authors: Shom Goel, Sir Peter MacCallum Department of Oncology, 305 Grattan Street, Melbourne, Victoria 3000, Australia. E-mail: [shom.goel@petermac.org](shom.goel@petermac.org); and Patrick Roberts, Incyclix Bio, 600 Park Offices Drive, Suite 355, Research Triangle Park, NC 27709. E-mail: [proberts@incyclixbio.com](proberts@incyclixbio.com)  \nCancer Discov 2024;14:446–67  \ndoi: 10. 1158/2159-8290 . CD-23-0954  \nThis open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license.  \n©2023The Authors; Published by the American Associatio","cbCaijqSAxlIB7Qu","https://ap.wps.com/l/cbCaijqSAxlIB7Qu","pdf",32855276,22,"English","# Abstract\n# Significance\n# Introduction","[{\"question\":\"What problem does the study address regarding CDK2 inhibition?\",\"answer\":\"The precise effects of pharmacologic CDK2 inhibition are unclear because selective CDK2 inhibitors were lacking. The work introduces INX-315 to fill this gap and evaluate its impact on tumor cell behavior.\"},{\"question\":\"How does INX-315 affect CCNE1-amplified tumors?\",\"answer\":\"INX-315 promotes retinoblastoma protein hypophosphorylation and therapy-induced senescence, leading to durable control of tumor growth in CCNE1-amplified contexts.\"},{\"question\":\"How does INX-315 relate to resistance to CDK4/6 inhibitors in breast cancer?\",\"answer\":\"INX-315 overcomes breast cancer resistance to CDK4/6 inhibitors by restoring cell cycle control and re-establishing the chromatin architecture associated with CDK4/6i-induced therapy-induced senescence.\"}]","INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors | PDF",1790007416,55]